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Background: Network meta-analysis methods extend the standard pair-wise framework to allow simultaneous
comparison of multiple interventions in a single statistical model. Despite published work on network meta-analysis
mainly focussing on the synthesis of aggregate data, methods have been developed that allow the use of individual
patient-level data specifically when outcomes are dichotomous or continuous. This paper focuses on the synthesis
of individual patient-level and summary time to event data, motivated by a real data example looking at the
effectiveness of high compression treatments on the healing of venous leg ulcers.
Methods: This paper introduces a novel network meta-analysis modelling approach that allows individual patient-level
(time to event with censoring) and summary-level data (event count for a given follow-up time) to be synthesised
jointly by assuming an underlying, common, distribution of time to healing. Alternative model assumptions were tested
within the motivating example. Model fit and adequacy measures were used to compare and select models.
Results: Due to the availability of individual patient-level data in our example we were able to use a Weibull
distribution to describe time to healing; otherwise, we would have been limited to specifying a uniparametric
distribution. Absolute effectiveness estimates were more sensitive than relative effectiveness estimates to a
range of alternative specifications for the model.
Conclusions: The synthesis of time to event data considering individual patient-level data provides modelling
flexibility, and can be particularly important when absolute effectiveness estimates, and not just relative effect
estimates, are of interest.
Keywords: Evidence synthesis, Time to event data, Survival data, Individual patient data, Aggregate data,
Meta-analysis, Mixed treatment comparisons, Network-meta-analysis, Treatment-effect modifiersBackground
Treatment decisions in medicine, whether at the patient-
or policy level, should consider all relevant alternative
health care technologies potentially capable of delivering
the change being sought. Such informed decision making
on the use of competing treatments requires evidence of
relative effects from randomised controlled trials (RCTs)
(which may be further used to inform estimates of
cost-effectiveness). However, trying to synthesise evidence
from several different pair-wise comparisons relevant to a
decision problem can be challenging. A piecemeal approach
can be avoided if all RCTs evaluating interventions relevant
to the treatment decision are considered collectively, for* Correspondence: pedro.saramago@york.ac.uk
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unless otherwise stated.example, with the use of network meta-analysis (NMA).
NMA is a well-established statistical technique that extends
standard pairwise meta-analysis framework to allow simul-
taneous comparison of multiple interventions in a single
statistical model [1,2]. This approach then produces relative
effect estimates (and associated descriptions of uncertainty)
for all treatments connected by the network of evidence
[3] – even where head-to-head trials for comparisons do
not exist.NMA using individual patient data
Published work on NMA mainly focuses on the synthesis
of aggregate data (AD) (sometimes called summary data,
e.g. group means and standard errors available from study
reports) [4,5]; however, methods have been developed that
allow use of individual patient-level data (IPD) in NMA,ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Saramago et al. BMC Medical Research Methodology 2014, 14:105 Page 2 of 11
http://www.biomedcentral.com/1471-2288/14/105specifically for binary and continuous data [6-8]. The
appeal of including IPD in a NMA is that it is likely to
reduce statistical heterogeneity across the network (and in
this way help resolve possible inconsistencies); it may also
allow subgroup effects to be estimated which in turn
could guide more personalised treatment decisions [6].
The use of IPD, alone or in combination with AD, has
been shown to improve inference in NMAs where the
outcome of interest is binary (dichotomous) by aiding
convergence, and by providing unbiased treatment–
covariate interactions (that would otherwise be affected
by ecological bias [9]). For continuous outcomes, IPD is
likely to produce more precise estimates of treatment
effects, even in the absence of treatment–covariate in-
teractions [10].
NMA using time to event related outcome data
When undertaking an NMA, aggregate time to event
data presented as hazard ratios (HR), and some measure
of uncertainty around these estimates, can be pooled
directly using standard methods (analogous to pooling
odds ratios or relative risks) [11]. However, other AD
outputs such as median/mean time to event [12] and
cumulative counts of patients having the outcome event
in a period of time [13] have also been meta-analysed in
a network. In modelling these data, an underlying time
to event distribution can be specified which will then
allow HRs to be generated from the original AD [5,14,15].
To date, evidence synthesis that includes IPD on time to
event has been limited to pairwise analysis; additionally
there has been little methodological exploration how
outcomes in the form of IPD and AD might be considered
together in the same NMA [13].
Developing a NMA combining AD and IPD data to
synthesise time to event related outcomes
This paper describes a modelling framework that com-
bines AD and IPD in the synthesis of time to event
related outcomes within an NMA. It extends the work
of Saramago et al. [6] and Sutton et al. [16] on the syn-
thesis of AD and IPD for binary data to consider time
to event outcomes. And extends the work on NMAs
for time to event AD outcomes by Soares et al. [15]
and Woods et al. [14] (the general modelling frame-
work is also described in Dias et al. [5]). Our work was
motivated by an NMA on treatments for healing ven-
ous leg ulcers, for which we had data from multiple
RCTs (more information provide in the next section).
A proportion of the RCT data on ulcer healing was
available in IPD format (time to healing and time to
censoring), with the remaining data available as AD, i.e.
count data (proportion of patients healed at end of
follow-up which differs across studies). To maximally
draw from available data we aimed to jointly synthesisethe available AD and IPD, and, in this way, generating
better estimates and providing fuller characterisations of
uncertainty to best inform decisions on the use of the treat-
ments of interest.
Motivating example: high compression treatments for
venous leg ulcers
The case study relates to compression systems aiming to
deliver high compression (classed as ≥40 mmHg compres-
sion at the ankle) to promote venous leg ulcer healing.
Available standardised systems are: two layer hosiery (HH),
the four layer bandage (4LB), the short stretch bandage
(SSB), the zinc paste bandage (ZINC), and the two layer
bandage system (2LB). A detailed description is provided
in Additional file 1 with further details of these systems
presented elsewhere [17].
Effectiveness evidence from RCTs was obtained from
the most recent update of the relevant Cochrane review
available to us, and from a recent multicentre RCT
which compared 4LB with HH. All available RCT evi-
dence was assessed for inclusion in the current NMA: a
detailed process that has been reported elsewhere [17].
The final NMA contained data from 16 RCTs on the
relative effectiveness of high compression systems for
the treatment of venous leg ulcers. Data for two of the
16 included RCTs (VenUS I and VenUS IV, hereby
denominated studies 1 and 2) had full IPD data available
(841 participants) which included time to healing or
censoring for each participant, together with other
individual-level characteristics such as treatment centre,
ulcer duration and size and also patient mobility. For
the remaining RCTs (1105 participants), aggregate data
on the number of healed ulcers were extracted from the
source review alongside information regarding treat-
ment type, number of participants allocated to each
treatment group, mean duration of follow-up (if this
was not stated, trial duration was used), mean ulcer
duration and size.
The 16 included RCTs described nine unique high
compression treatments: the five standard treatments
(4LB, SSB, ZINC, HH and the 2LB) and four ad hoc
systems [17]. The ad hoc group consisted of treatments
deemed irrelevant to current clinical practice, and are
not reported further (results can be provided upon request).
These studies were, however, included in the NMA as their
data was potentially relevant, for example, in describing
determinants of healing.
Table 1 describes the data available and Figure 1 presents
the treatment network formed by the evidence [17-32]. The
most populated comparison was the 4LB vs. SSB, in-
formed by seven RCTs: six with healing data available as
AD [18-22,31] and one as IPD [32]. The link between the
2LB and 4LB was informed by two RCTs and each of the
remaining six comparisons in the NMA were informed
Table 1 Analytic dataset












16 Duby et al. 1993 [18] 4LB 12 25 20.5 11.9 11 AD
SSB 12 25 26.7 13.1 10
17 Scriven et al. 1998 [19] 4LB 52 32 13 13.3 17.6 AD
SSB 52 32 21 8.3 18.24
18 Partsch et al. 2001 [20] 4LB 16 53 1.25 1.5 33 AD
SSB 16 59 1 1.9 43
19 Ukat et al. 2003 [21] 4LB 12 44 – 17.7 13 AD
SSB 12 45 – 12.2 10
20 Franks et al. 2004 [22] 4LB 24 74 2 5 59 AD
SSB 24 82 2 3.5 62
21 Junger et al. 2004b [23] SSB 12 60 5.57 5.95 19 AD
HH 12 61 4.14 5.62 29
22 Kralj et al. 1996 [24] 4LB 24 20 7.9 18.6 7 AD
Ad hoc: Ba 24 20 6.9 17.2 8
23 Polignano et al. 2004b [25] 4LB 24 39 – 10.1 29 AD
ZINC 24 29 – 9.3 19
24 Wilkinson et al. 1997 [26] 4LB 12 17 – 11.2 8 AD
Ad hoc: BHeH 12 18 – 8.6 8
25 Colgan et al. 1995 [27] 4LB 12 10 9.3 27.5 6 AD
Ad hoc: BzeaH 12 10 66.5 48.5 7
26 Blecken et al. 2005 [28] 4LB 12 12 – 50.08 4 AD
Ad hoc: HV 12 12 – 48.98 4
27 Moffatt et al. 2008 [29] 4LB 4 42 48.8 5.7 3 AD
2LB 4 39 46.6 11.8 6
28 Szewczyk et al. 2010 [30] 4LB 12 15 – 6 9 AD
2LB 12 16 – 5.3 10
29 Wong et al. 2012 [31] 4LB 24 107 – – 72 AD
SSB 24 107 – – 77
30 Iglesias et al. 2004 [32] 4LB 52 195 3 3.81 107 IPD
SSB 52 192 3 3.82 86
14 Ashby et al. 2013 [17] 4LB 52 224 12.29 9.30 157 IPD
HH 52 230 10.82 9.41 163
AD – aggregate-level data; IPD – individual patient data; 4LB, SSB, HH, Zinc paste,2LB and the ad hoc systems Ba, BHeH, BzeaH, HV as described in
Additional file 1.
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(Table 1).
Methods
We first describe the modelling framework for our main
analysis, model A. This model brings together IPD and
AD into the same synthesis model, with both types of
evidence contributing to the estimation of all key models
parameters (i.e. absolute and relative effectiveness esti-
mates). We then detail the evaluation of alternative
assumptions applied to model A, thus highlighting andchallenging specific assumptions of the modelling frame-
work proposed. All synthesis was conducted in a Bayesian
framework.
Suppose there are two sets of studies, one set for
which IPD are available and one set for which AD are
available. Consider the set of studies to be T = {1,…,
number of IPD studies (NSIPD),…, NSIPD + number of AD
studies (NSAD)} where the total number of studies is J;
consider the set of treatments to be {1,2,3,…}, where






















Figure 1 Network of RCTs. In the network, a unique treatment category is indicated by a circle. Arrows between circles indicate that these
treatments had been compared in a trial (trials are identified using ‘[]’, numbered as in column ‘ID’ in Table 1. (4LB, SSB, HH, Ba, Zinc Paste, BHeH,
BzeaH, HV and 2LB as described in Additional file 1).
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We describe model A in two interrelated parts: part I
describes the modelling of the IPD and part II the mod-
elling of the AD.
Model A; part I− modelling the IPDstudies;








μIPDj þ γcj þ β0jxijk if k ¼ b
μIPDj þ dbk þ γcj þ β0xijk if k > b
xijk ∼N m; pð Þ γcj ∼N 0;πð Þ
ðA1Þ
Time to ulcer healing (tijk) of the i
th participant in the
jth study (where j =1,…, NSIPD) and in the k
th treatment
arm was assumed to be Weibull distributed [33] with
shapea. parameter, s, and scale, λijk. For some participants,
time to event was not observed, and these observations
were censored at the time the participant last had trial
data recorded, tcijk . The linear predictor log(λijk), was
modelled as a function of the log-hazard of an event for
the baseline treatment b, μIPDj , of the log of the treat-
ment effects, dbk and of a study-specific individual-level
regression term, β0jxijk, where β0j exemplifies a covariate
effect, i.e. the difference in the log hazard ratio per unit
increase in the covariate xijk a patient-level covariate for
the ith patient in the jth trial on treatment k available in
the IPD data sets [17]). The effect of each covariate on
the hazard of healing was assumed to be equal in both
IPD studies. Due to the possibility of missing covariateinformation existing for some individuals, xijk was rep-
resented as a Normally distributed random variable with
mean m and precision p, common across all IPD studies.
This is essentially a multiple imputation technique through
MCMCb. and assumes that the missingness mechanism
was at randomc.. Additionally, to account for centre
variability within each IPD study, γcj was defined for
each centre, c, in the jth study, these were combined
using a common frailty effect described by a normal
distribution with mean zero and precision τ.
The treatment effects, dbk, were log-hazard ratios for
treatment k relative to the study-specific baseline treat-
ment b, partitioned further as d1k − d1b. This equation
defines the set of functional parameters, that is the log
effects of each treatment in relation to the reference
treatment 1. Note that d11 = 0, where treatment 1 was
4LB, arbitrarily chosen as reference treatment.
Vague prior distributions were specified for μIPDb

∼N 0; 106
   for the regression coefficient β0j (∼N(0, 106))
for m(∼N(0, 106)) and p(∼Gamma(0.01, 0.01)) for the
shared centre effect τ(∼Gamma(0.01, 0.01)), for s(∼Gamma
(0.01, 0.01)) and for d1k ∼N(0, 10
6).
Model A; part II − modelling theADstudies
rjk∼Bin pjk ; njk
 






j if k ¼ b
μADj þ dbk if k > b
(
ðA2Þ
Within the AD studies, the observed number of partici-
pants with a healed ulcer within each study, rjk, out of the
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NSIPD+1,…, (NSIPD+ NSAD)] and k
th treatment (intention
to treat), njk, was assumed to be Binomially distributed.
The underlying probabilities of an event for each arm and
in each trial were represented by pjk. In turn, pjk was
expressed as a function of the scale parameter, λADjk , of
follow-up time, tADjk , and the shape parameter, s, of the
Weibull distribution. The linear predictor, log λADjk
 
was a function of the baseline log-hazard of an event
for treatment b in study j, μADjb , and by the log-hazard
ratio for treatment k and baseline treatment b, dbk
(=d1k − d1b) Note that there are parameters common to
both model parts (equations A1 and A2), namely the
log-hazard ratios and the shape parameter of the time
to healing distribution. Vague prior distributions were





Underlying model A are a set of assumptions that are
detailed below. Such assumptions have been relaxed in
models B to D.
Exploring between-study variation
Model A assumed that each included RCT aimed to meas-
ure a common treatment effect (fixed-effect); however, it
is likely that there was between-study variation. Model B
included a random effect to characterise between-study
heterogeneity, where dbk was replaced by a study specific
δjbk, that is then described by a Normal distribution with
mean dbk and precision, prec – this is common to both
parts I (eq. A1) and II (eq. A2).
Time to healing distributions
Model A used the Weibull distribution to describe time
to healing. Our choice of survival distribution was lim-
ited as distributions such as the Log-Logistic or the
Log-Normal do not allow the probability of healing
over time to be expressed in a closed form, and hence
impede the approach proposed here for the joint syn-
thesis of IPD and AD. Other distributions, such as the
Gompertz, were not readily defined within the software
used in this work (WinBugs/OpenBugs), specifically
under censoring. Nonetheless, the goodness of fit could
still be assessed in each IPD data source individually. To
do this, we applied parametric regression survival-time
models [33] to both IPD data sources [17,32] inde-
pendently (covariates and frailty effect considered, as
in model A).
Distributional shape parameter
Model A assumes that the Weibull shape parameter of the
hazard of healing was common to both IPD data sources.It is possible that this parameter differed between studies,
in which case HRs could be affected. Thus, we imple-
mented two alternative NMA models to ascertain the
impact of this assumption on the relative effectiveness
estimates: model C1 used the shape parameter from the
first IPD study to describe the AD studies and model C2
used the shape parameter from the second IPD study to
describe these same studies. Because models C1 and C2
represent simple modifications of model A we do not
present these algebraically.
Treatment-covariate associations
Model A uses baseline covariates to adjust for clinical het-
erogeneity in the IPD. To further explore the impact of
covariates on the relative treatment effects (i.e. whether
they were effect modifiers), and potentially help explain
between-study heterogeneity, we also included interaction
terms between alternative treatments and baseline ulcer
area and duration— as described by Cooper et al. 2009
[34] and Saramago et al. 2012 [6]. Model D assumed a
regression (slope) coefficient for the interaction terms, this
effect was common across treatments and thus common
to parts I (eq. D1) and II (eq. D2). This assumption was
data driven, as this was the only option we were able to
implement with the data available (i.e. compared to
assuming ‘exchangeability’ or ‘independence’). Note
that interaction estimates obtained were influenced by
the full evidence base for which study mean covariate(s)
values were available, including trials considering ad hoc
treatments.
Model D, part I- modelling the IPD studies, considering
common treatment-by-covariate interactions










μIPDb þ γcj þ β0jxijk if k ¼ b
μIPDb þ γcj þ β0jxijk þ dbk þ βxijk if k > b
xijk∼N m; pð Þ γcj∼N 0; τð Þ
ðD1Þ
Time to ulcer healing was modelled in the same way
as in model A (equation A1). A treatment-by-covariate
interaction regression term, βxijk, was defined, where β
is the association effect, assumed common across studies
and the same regardless of treatment (excluding con-
trol). We included no interaction term for each compari-
son of k versus b when b ≠ 1 because the common
regression coefficient cancels out; but, as β11 = 0, we in-
cluded an interaction term for each comparison of k ver-
sus treatment 1. For the remainder of the parameters of
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model A.
Model D; part II − modelling the ADstudies; considering
common treatment−by−covariate
interactions
rjk∼Bin pjk ; njk
 






jb if k ¼ b
μADjb þ dbk þ βxj if k > b
(
ðD2Þ
In part two of model D, xj represented the mean covari-
ate value for the jth trial ((where j = NSIPD+1,…, (NSIPD+
NSAD)). Both the IPD and AD contributed to the esti-
mation of this interaction term (i.e. same β term in
equations D1 and D2). All other components of the
model were as described for model A.
Model selection and implementation
The NMA analyses were undertaken in the WinBUGs
software [35]. In all models the MCMC sampler was run
for 10 000 iterations and these were discarded as ‘burn-in’.
Models were run for a further 5000 iterations, on which
inferences were based. Chain convergence was assessed by
running the model for two disparate sets of initials values,
and by then checking that the Brooks-Gelman-Rubin
diagnostic converges to 1.0. The WinBUGS code is
included for reference in Additional file 2. Within the
NMA, goodness of fit was assessed using the deviance
information criterion (DIC) [36]. Results were presented
using hazard ratio estimates (and associated credibility
intervals, CrIs) and also using the probability of each
compression system being the ‘best’ treatment in terms
of being the most clinically effective [37].
The statistical software STATA [38] was used to fit
alternative time to event distributions to the IPD data-
sets individually. Goodness of fit was assessed with the
Akaike Information Criteria (AIC) statistic [39].
Results
Table 2 shows parameter estimates obtained for model A
(first column) and alternative models relaxing its assump-
tions (models B to D, second to fifth columns). Model A
considers the baseline information for the following covar-
iates: the log of the ulcer area (in cm2) and duration (in
months) - both centred to its sample mean; and dummies
generated from a categorical variable on participants’
mobility with three categories (‘immobile’, ‘walks with
difficulty’ and ‘walks freely’, the latter being the reference
category). The results for model A highlight that the
modelling framework proposed is feasible. A graphicalrepresentation of model A results is shown in Figure 2.
This plots the probability of healing over time for the
five main high compression ulcer treatments, but con-
siders only the uncertainty over relative treatment effects.
The results of testing the assumptions are described next.
Exploring between-study variation
Despite estimates of HRs from the random effect model
(model B) being associated with wider CrIs than those
from model A (as expected), point estimates were found
to be fairly similar except for the comparison between
HH vs. 4LB: HH is estimated to be more effective in
model B (HR 1.63, 95% CrI 0.76-3.53) compared to
model A (HR: 1.05, 95% CrI 0.85 to 1.29), although the
CrI of the former includes the later. The treatment with
the greatest estimated probability of healing was HH in
model B (59%), rather than 2LB (72%) as in model A.
Differences may be explained by any existing variation
between studies of SSB vs. 4LB indirectly impacting on
the evidence loop 4LB vs. SSB vs. HH. Baseline covariate
effect estimates remained similar. However, note that the
gain in quality fitting of the random-effects model com-
pared to the fixed-effects is null (DIC: 5396.21 and
5396.22, respectively). Previous published work assessing
evidence on the SSB vs. 4LB comparison [40] similarly
found no evidence of between-study heterogeneity.
Time to healing distributions
The Weibull was used to describe time to healing in
model A. Whilst we were limited in the use of other
distributions, goodness of fit was explored by applying
alternative time to event distributions to the IPD studies
individually. Table 3 shows results of such analysis (AIC
statistic) and Additional file 3 graphically presents the fit-
ted curves and the Kaplan Meier counterpart for control
arms. The best fitting distributions for both studies were
the Log-Logistic and Log-Normal. Of the remaining, the
Weibull and Gompertz distributions provided better fit
than the Exponential; this was expected given the flexibil-
ity of these distributions in assuming increasing, decreas-
ing or constant hazards over time. The Weibull was best
in IPD study 2 and the Gompertz best in IPD study 1.
Distributional Weibull shape parameter of healing hazard
The Weibull shape parameters estimated within models
C1 and C2 indicate that in IPD study 1 [32] the hazard
of healing was expected to decrease over time (s1 = 0.93,
95% CrI 0.86-1.01), while in IPD study 2 it is expected
to increase (s2 = 1.27, 95% CrI 1.17-1.38). Note that
there is no overlap in the CrIs. However, results show
that relative effectiveness estimates are robust to the
range of assumptions tested: the estimated HRs did not
differ between models C1 and C2, and did not substantially
differ from model A.
Table 2 Parameter estimates from the alternative MTC synthesis models
Model A Model B Model C1 Model C2 Model D











Treatment effects 4LB — — 5.5 — — 1.4 — — 6.2 — — 5.7 — — 4.3
SSB 0.88 (0.76, 1.03) 0.4 0.96 (0.77, 1.22) 0.6 0.89 (0.77, 1.04) 0.6 0.89 (0.77, 1.04) 0.6 0.84 (0.70, 0.99) 0.2
HH 1.05 (0.85, 1.29) 16.1 1.63 (0.76, 3.53) 59.2 1.03 (0.83, 1.27) 14.9 1.03 (0.84, 1.27) 15.0 1.03 (0.84, 1.28) 11.1
ZINC 0.77 (0.41, 1.42) 6.2 0.78 (0.37, 1.62) 2.8 0.78 (0.41, 1.44) 6.5 0.78 (0.41, 1.43) 6.7 0.75 (0.03, 29.49) 17.5
2LB 1.40 (0.65, 3.05) 71.9 1.39 (0.62, 3.30) 36.0 1.38 (0.66, 3.05) 71.8 1.38 (0.63, 3.04) 72.0 1.59 (0.61, 5.34) 67.0
Baseline characteristics Log area 0.71 (0.66, 0.76) — 0.71 (0.66, 0.76) — 0.70 (0.65, 0.75) — 0.70 (0.65, 0.75) — 0.71 (0.65, 0.76) —
Log duration 0.92 (0.90, 0.94) — 0.92 (0.90, 0.94) — 0.92 (0.91, 0.94) — 0.93 (0.91, 0.94) — 0.92 (0.90, 0.94) —
Difficulty in walking 0.71 (0.60, 0.85) — 0.73 (0.60, 0.86) — 0.72 (0.60, 0.85) — 0.72 (0.60, 0.85) — 0.71 (0.60, 0.80) —
Immobile 0.67 (0.23, 1.52) — 0.66 (0.23, 1.51) — 0.72 (0.24, 1.65) — 0.72 (0.25, 1.67) — 0.68 (0.24, 1.59) —
Interactions Log area — — — — — — — — — — — — 1.00 (0.97, 1.10) —
Log duration — — — — — — — — — — — — 1.00 (0.99, 1.00) —
Btw-centre SD 0.04 (0.01, 0.13) — 0.05 (0.01, 0.13) — 0.05 (0.01, 0.15) — 0.05 (0.01, 0.15) — —
Btw-study SD — — — 0.13 (0.01, 0.51) — — — — — — — — — —
λ 1.07 (1.01, 1.13) — 1.07 (1.01, 1.14) λ1** 0.93 (0.86, 1.01) λ1 0.93 (0.86, 1.01) — 1.07 (1.01, 1.14) —
λ2 1.27 (1.17, 1.38) λ2** 1.27 (1.17, 1.38)
DIC 5396.2 5396.2 5371.2 5371.5 5377.4
Model A – Fixed-effects NMA, Weibull model of IPD+AD; model B – Random-effects NMA, Weibull model of IPD+AD; model C1 - Fixed-effects NMA, Weibull model of IPD+AD, shape parameter derived from IPD study 1
only; model C2 - Fixed-effects NMA, Weibull model of IPD+AD, shape parameter derived from IPD study 2 only; model D - Fixed-effects NMA, Weibull model of IPD+AD, considering 2 treatment-effect modifiers.
**Shape parameter used in the synthesis model section for summary data.
4LB = four layer bandage; SSB = Short stretch bandage; HH = two layer hosiery; 2LB = two layer bandage.





















Figure 2 Graphical representation of model A results reflecting uncertainty over relative treatment effects in the probability of healing
over time for the five main high compression ulcer treatments. The main figure (a) shows the expected probabilities of healing (point
estimates) across time (25 months); figures (b), (c), (d) and (e) compare the expected values for four layer bandage with the healing probability
(point estimates and uncertainty) of each of the other four high compression treatments. Estimates reflect the average participant in the trial data
from VenUS IV (IPD study 2) (mean ulcer area at baseline of 9.4cm2 and ulcer duration at baseline of 11.5 months). (4LB, SSB, HH, Zinc Paste and
2LB as described in Additional file 1).
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Model D tested the inclusion of interaction terms. Two
covariates on ulceration area (in cm2) and duration (in
months) were considered and their association with
treatment evaluated. Results (column 5 of Table 2) show
that the covariates included did not appear to be treatment
effect modifiers in this case study. However, estimating
these two additional regression terms increased uncertainty
in relative treatment effects estimates, specifically for ZINC
and 2LB.Table 3 Goodness of fit (AIC statistics) of alternative time
to ulcer healing models for IPD studies 1 and 2
Time to event model
Akaike Information Criteria (AIC)
IPD study 1 (30) IPD study 2 (14)
Weibull PH 1102.1 1021.0
Gompertz PH 1072.5 1065.5
Exponential PH 1102.7 1068.4
Log-Logistic AFT 1026.1 971.8
Log-Normal AFT 1032.2 961.5
PH = proportional hazards model; AFT = accelerated failure time modelDiscussion
This paper introduces a novel NMA modelling approach
that allows IPD on time to event (with censoring) and
AD on event count (for a given follow-up time) to be
synthesised jointly, by assuming an underlying, common,
distribution of time to healing. Available IPD is used
directly to inform this distribution (likelihood). Studies
reporting the number of participants healed (AD) are
used to inform a probability parameter, and a Binomial
likelihood was defined for this subset of the evidence-
set. The probability of healing was then related (algebra-
ically) to the common distribution of time to healing, by
taking the duration of follow-up in each AD study into
account. This modelling framework extends approaches
in the literature [5,14,15] and is also a natural extension
of previously published methodologies of synthesising
IPD and AD jointly [6-8,16]. This work was motivated
by a real data example looking at the effectiveness of high
compression treatments on the healing of venous leg
ulcers.
We found that the key strength of the use of IPD in this
context (additional to the known advantages described in
the introduction) was the flexibility in modelling these
data allowed. For example, had all evidence been available
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the specification of uniparametric distributions for time to
healing i.e. the Exponential, with constant healing hazard
over time [5,14,15]. In our motivating example, the Expo-
nential distribution was shown to be less adequate than
other distributions in describing the time to event data in
the studies for which IPD were available. The availability
of IPD allowed a more complex distribution for time to
event outcomes to be implemented, in this case the
Weibull. This may be of particular importance when ab-
solute effectiveness estimates, and not just relative effect
estimates, are of interest – and especially where results
may need to be extrapolated beyond the follow-up time
horizon.
We note that even with the flexibility offered by the
use of IPD we were, in practice, limited to using the
Weibull distribution. Semi-parametric methods are also
unmanageable as the evidence in aggregate form consists
of a single data point and thus does not allow defining a
non-parametric distribution of hazard of healing. Given
this limitation, the synthesis of time to event data will
still often require the use of potentially suboptimal distri-
butional assumptions, in which case estimates obtained
may be biased. We suggest further research could focuses
on using numerical analysis techniques within NMA, to
try and resolve this issue.
This work was also relevant in again highlighting the
importance of including IPD when wanting to consider
patient characteristics in the model. In the presence of
heterogeneity, incorporating information on either a) pa-
tients’ baseline characteristics or b) control for treatment-
effect modifiers within the synthesis model has been
shown to improve estimates and, by doing so, possibly
resolve evidence inconsistencies [6,34]. The first relates to
potential heterogeneity in the baseline hazard, which can-
not be explicitly explored with AD alone (this is important
when analyses aim to explore determinants of baseline
hazard, for example). In this study we assumed a common
effect of baseline covariates on the hazard of healing
across IPD studies (as commonly assumed in IPD meta-
analysis). The second relates to treatment-covariate in-
teractions, which are generally acknowledged to be best
estimated using IPD, as ecological bias can be avoided
[9]. For the proportion of evidence only available as AD,
the model here implemented considered study level mean
covariate values. Nonetheless, not all studies provided
information for these, and imputation was undertaken
(imputation is naturally done through the MCMC, and as-
sumes values are ‘missing at random’).
In our work we assumed the shape parameter of the
Weibull time to event distribution to be common across
studies. However, testing proved this assumption was
not valid, thus highlighting the importance of evaluating
any assumptions of similarity imposed across studies.Despite relative effectiveness estimates being mainly
unaffected, such potential heterogeneity between studies
should be explored and accounted for in analyses. Such
assumptions of commonality also mean that information
may be shared throughout the network, in which case
evidence on treatments other than those on our decision
set (the five treatments of interest for which results were
reported). This is the case of model D that makes use of
all evidence (including ad hoc treatments) to estimate
treatment-covariate interaction, which may indirectly
affect the relative effectiveness estimates of interest.
In the network of evidence there was one closed loop
where both direct and indirect data informed relative
treatment effect estimates. The existence of inconsistency
was explored elsewhere [17], showing no evidence of sta-
tistically significant discrepancies between the direct and
the indirect data. We note, however, that given the fairly
high uncertainty in the evidence base, only large differ-
ences in direct and indirect data within the loop would
have returned a statistically significant result.
The evidence included as AD in our case study was
limited to the primary outcome data on proportion of
patients healed at the end of follow-up. However, we
could have extended the modelling framework to use any
other summary data reported, such as number of patients
healed at different time points or Kaplan-Meier (KM)
curves. Information conveyed in Kaplan Meier plots can
be reconstructed [41], and further research could focus on
including this information in our NMA modelling frame-
work to strengthen inferences.
Conclusions
The use of IPD for a time to event outcome is particu-
larly useful in guiding HTA decision making by allowing
flexibility in the specification of more appropriate survival
distributions and in dealing with potential existing study
heterogeneity [42]. Increasingly, data sharing is promoted
in research [43,44] and this example highlights how use
of IPD allows the development of more informative and
flexible models that are better able to summarise exist-
ing evidence. However, it is important to acknowledge
that accessing and analysing IPD can be time consuming
and may cause delay [4]. The process needs to be well
planned and implemented. In our case both sources of
IPD were easily accessed and that directly facilitated the
conduct of these analyses and the associated methodo-
logical work presented here.
Endnotes
a.The shape parameter of the Weibull distribution, s, can
be interpreted directly as follows: i) if 0 < s < 1, hazard
rate decreases over time; ii) if s = 1, hazard rate is
constant over time (hazard exponentially distributed); and
if s > 1, it indicates that the hazard increases with time.
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independent draws of the missing data from its predict-
ive distribution. Multiple imputation through MCMC
techniques is attractive for exploratory or multi-purpose
analyses involving a large number of estimands.
c.The missing-at-random assumption (sometimes called
the ignorability assumption) considers that the probabil-
ity that an observation is missing may depend on the
observed values but not the missing values, as sufficient
data has already been collected.
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